Cargando…
Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects
Background: Topical application of tacrolimus (FK506) was effective in treating atopic dermatitis (AD); however, the therapeutic efficiency is hampered by its poor penetration into the skin and local side effects of transient irritation symptoms with a burning sensation, a feeling of warmth or heat....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679700/ https://www.ncbi.nlm.nih.gov/pubmed/31440050 http://dx.doi.org/10.2147/IJN.S212260 |
_version_ | 1783441391180840960 |
---|---|
author | Wang, Yixuan Cao, Sisi Yu, Kaiyue Yang, Fengdie Yu, Xiuming Zhai, Yuanhao Wu, Chuanbin Xu, Yuehong |
author_facet | Wang, Yixuan Cao, Sisi Yu, Kaiyue Yang, Fengdie Yu, Xiuming Zhai, Yuanhao Wu, Chuanbin Xu, Yuehong |
author_sort | Wang, Yixuan |
collection | PubMed |
description | Background: Topical application of tacrolimus (FK506) was effective in treating atopic dermatitis (AD); however, the therapeutic efficiency is hampered by its poor penetration into the skin and local side effects of transient irritation symptoms with a burning sensation, a feeling of warmth or heat. Menthol and camphor have been widely used in topical compound formulations for adjunctive pharmacotherapy for antipruritics and analgesics owing to their cool nature, and both present skin penetration enhancing effects. Moreover, they can form a liquid eutectic oil to solubilize hydrophobic drugs. Purpose: Taking advantages of menthol/camphor eutectic (MCE), this work aims to integrate FK506 into MCE to construct a microemulsion system, i.e., FK506 MCE ME, which simultaneously enhances the percutaneous delivery and treatment efficacy, while reduces the side effects of FK506. Methods: The formulation of FK506 MCE ME was optimized and characterized. Different formulations containing FK506 were topically administered to treat 1–chloro–2, 4–dinitrobenzene (DNCB)-induced murine AD. Results: MCE solubilized FK506. FK506 in MCE ME penetrated skin in vitro more than in the commercial ointment, and MCE predominantly exerted the enhancing effects in MCE ME. FK506 MCE ME or FK506 MCE ME gel had greater effects on clinical symptoms, histological analysis, and IgE than did commercial FK506. The anti-pruritic and down-regulation of substance P effects of MCE ME vehicle mitigated the side effects of FK506 application. Conclusion: MCE ME presented the excellent properties of simultaneously enhancing the percutaneous delivery and treatment efficacy, while reducing the side effects of FK506 for AD. Therefore, MCE ME is a promising nanoscale system for FK506 to effectively treating AD with low irritation and high medication adherence. Chemical compounds studied in this article: Tacrolimus (PubChem CID: 445643); menthol (PubChem CID: 1254); camphor (PubChem CID: 2537) |
format | Online Article Text |
id | pubmed-6679700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66797002019-08-22 Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects Wang, Yixuan Cao, Sisi Yu, Kaiyue Yang, Fengdie Yu, Xiuming Zhai, Yuanhao Wu, Chuanbin Xu, Yuehong Int J Nanomedicine Original Research Background: Topical application of tacrolimus (FK506) was effective in treating atopic dermatitis (AD); however, the therapeutic efficiency is hampered by its poor penetration into the skin and local side effects of transient irritation symptoms with a burning sensation, a feeling of warmth or heat. Menthol and camphor have been widely used in topical compound formulations for adjunctive pharmacotherapy for antipruritics and analgesics owing to their cool nature, and both present skin penetration enhancing effects. Moreover, they can form a liquid eutectic oil to solubilize hydrophobic drugs. Purpose: Taking advantages of menthol/camphor eutectic (MCE), this work aims to integrate FK506 into MCE to construct a microemulsion system, i.e., FK506 MCE ME, which simultaneously enhances the percutaneous delivery and treatment efficacy, while reduces the side effects of FK506. Methods: The formulation of FK506 MCE ME was optimized and characterized. Different formulations containing FK506 were topically administered to treat 1–chloro–2, 4–dinitrobenzene (DNCB)-induced murine AD. Results: MCE solubilized FK506. FK506 in MCE ME penetrated skin in vitro more than in the commercial ointment, and MCE predominantly exerted the enhancing effects in MCE ME. FK506 MCE ME or FK506 MCE ME gel had greater effects on clinical symptoms, histological analysis, and IgE than did commercial FK506. The anti-pruritic and down-regulation of substance P effects of MCE ME vehicle mitigated the side effects of FK506 application. Conclusion: MCE ME presented the excellent properties of simultaneously enhancing the percutaneous delivery and treatment efficacy, while reducing the side effects of FK506 for AD. Therefore, MCE ME is a promising nanoscale system for FK506 to effectively treating AD with low irritation and high medication adherence. Chemical compounds studied in this article: Tacrolimus (PubChem CID: 445643); menthol (PubChem CID: 1254); camphor (PubChem CID: 2537) Dove 2019-07-30 /pmc/articles/PMC6679700/ /pubmed/31440050 http://dx.doi.org/10.2147/IJN.S212260 Text en © 2019 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wang, Yixuan Cao, Sisi Yu, Kaiyue Yang, Fengdie Yu, Xiuming Zhai, Yuanhao Wu, Chuanbin Xu, Yuehong Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects |
title | Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects |
title_full | Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects |
title_fullStr | Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects |
title_full_unstemmed | Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects |
title_short | Integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects |
title_sort | integrating tacrolimus into eutectic oil-based microemulsion for atopic dermatitis: simultaneously enhancing percutaneous delivery and treatment efficacy with relieving side effects |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679700/ https://www.ncbi.nlm.nih.gov/pubmed/31440050 http://dx.doi.org/10.2147/IJN.S212260 |
work_keys_str_mv | AT wangyixuan integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects AT caosisi integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects AT yukaiyue integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects AT yangfengdie integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects AT yuxiuming integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects AT zhaiyuanhao integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects AT wuchuanbin integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects AT xuyuehong integratingtacrolimusintoeutecticoilbasedmicroemulsionforatopicdermatitissimultaneouslyenhancingpercutaneousdeliveryandtreatmentefficacywithrelievingsideeffects |